News

You are here

Apr 10, 2017

Barcelona hosted BIO-Europe Spring 2017, one of the reference events for European biotech and pharma companies. Iproteos not only participated in the partnering, but it also was selected to participate in the Startup Slam, a pitching competition organized by Johnson&Johnson Innovation and EBD Group.

Jan 26, 2017

The Spanish Ministry of Economy, Industry and Competitiveness has granted a project for the validation of a new family of drug candidates for the treatment of vascular cholesterol accumulation associated with atherosclerosis.

Dec 19, 2016

Iproteos, in collaboration with the group of Prof. Javier Meana, from the University of Basque Country and CIBERSAM, and Prof. Giralt, from IRB Barcelona, has just published an article at European Neuropsychopharmacology. The paper, entitled "The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia", describes the efficacy of a novel procognitive drug for the treatment of Cognitive Impairment Associated to Schizophrenia (CIAS).

Oct 25, 2016

Iproteos has closed a funding round of 1.5M €, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech Ascil Biopharm.

Aug 30, 2016

The city of Barcelona will host the 27th CPhI Worldwide. The event, that will take place on 4th-6th October 2016, is an excellent scenario for networking in the pharma business. More than 36,000 professionals will attend CPhI Worldwide, fact that contributes to make this event one of the most important shows for pharma industry and a must attend event. The key pharma sectors are represented, including ingredients, APIs, excipients, finished dosage and contract services among others.